Age-Related Macular Degeneration Therapeutics Pipeline Analysis, Clinical Trials, Results, Patent and Other Developments

 

According to a new research report “Age-related macular degeneration Therapeutic Pipeline Analysis, 2017 – Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Age-related macular degeneration Therapeutic pipeline currently exhibits a pipeline with 55 drug candidates.

The Age-related Macular Degeneration pipeline analysis report covers approximately 55 drug candidates in the pipeline in different stages of development.

As per the findings of the research, most of the drug candidates of Age-related macular degeneration pipeline are being developed to be administered by intra-vitreal route.

 

Make Enquiry Before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=age-related-macular-degeneration-market

 

Many technologies are being developed that can bring the innovative treatment which can control the progression of Age-related macular degeneration. Some of these technologies include but are not limited to, HINGESCREEN technology platform, and CrossMab technology platform.

There are different novel molecule types that are present in the therapeutic pipeline of Age-related macular degeneration. Opregen is being developed by Cell Cure Neurosciences. Opregen is a stem cells molecule type useful in the treatment of Age-related macular degeneration.

 

Some of the key players developing drugs for Age-related macular degeneration include Formycon, AG, Allergan Plc, Hoffmann-La Roche, and others.

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Designed by CyFocus.com
Powered by CyFocus.net
%d bloggers like this: